2020 General Assembly + Immunotherapy


15th February 2020

KU Leuven, Herestraat 49,
campus Gasthuisberg
Onderwijs & Navorsing 2 (O&N2) building,
auditorium BMW2.
Parking “Villa”: Entrance code 3404#

Registration Deadline: February 7, 2020

RIZIV/INAMI: activity number: 19057854; 2,5 credits (category: general)

BELNUC session: 02h00 for NM physicians (NM)

This seminar is supported by:


09:00 – 09:45

Candidates for BELNUC board are:

  • Next BELNUC President Elect 2020-2021 (President 2022-2023):

Prof Dr Koen Van Laere, KU Leuven

  • Next BELNUC General Secretary Elect 2020-2021 (GenSec 2022-2023)

Dr Géraldine Gebhart, Bordet Institute, Brussels

  • Board member 2020-2022 (physician or physicist)

Dr Cédric Reichel, Cliniques de Jolimont, La Louvière


  1. 2019 Accounts
  2. 2019 membership
  3. Bank accounts statements
  4. BELNUC administration
  5. BELNUC services
  6. BELNUC 2019 activities
  7. BELNUC workgroups
  8. BARR section
  9. Technologists section
  10. 2020 and 2021 membership fees to be approved
  11. 2020 Budget
  12. Board members discharge: Karolien Goffin, Nadia Withofs and Pieter De Bondt
  13. Presentation of board members candidates
  14. Voting

Coffee break

10:00 – 10:30
The nuts and bolts of immunotherapy: victories and challenges.
prof. dr. Evelien Smits
Center for Oncological Research
University of Antwerp
Antwerp, Belgium

10:30 – 11:15
Potential of molecular imaging to select patients for immunotherapy in cancer.
prof. dr. Egbert F. Smit
Thoracic Oncology Service
Netherlands Cancer Institute
Amsterdam, The Netherlands

Coffee break

11:45 – 12:30
Cancer immunotherapy treatment response criteria in clinical practice and imaging hallmarks of treatment toxicity.
prof. dr. Egesta Lopci
Nuclear Medicine Department
Humanitas Clinical and Research Hospital
Milan, Italy

This seminar is supported by: